Revolutionizing Cancer Treatment: ExSURE PVT. LTD. Secures $348,000 in Seed Funding for Groundbreaking Exosome-Based Drug Delivery Platform

ExSURE PVT. LTD. is thrilled to announce that it has successfully raised $348,000 in its latest funding round, marking a significant milestone in the development of next-generation cancer therapeutics. As a pioneering research and development startup, ExSURE is dedicated to advancing the field of oncology through its innovative exosome-based chemotherapeutic drug-delivery platform. This groundbreaking approach allows for precise and guided delivery of existing anti-cancer drugs directly into tumor cells and relapse-causing cancer stem cells, all while minimizing harm to healthy tissues. With this funding, ExSURE aims to accelerate the validation of its platform, which has already demonstrated impressive efficacy in vitro and ex-vivo using various breast cancer models. The capital will be strategically directed towards scaling up research initiatives, including in vivo validation in SCID mice, and moving closer to clinical applications. Additionally, the funds will support the finalization of the patent for their bioengineered, drug-loaded targeted exosomes, enabling the company to secure its intellectual property and drive further innovation. Alongside therapeutic development, ExSURE also offers outsourcing services in cell culture-based assays and exosome experimentation, reinforcing its position as a comprehensive solution provider in the oncology research landscape. This funding underscores the growing confidence in ExSURE’s vision to transform cancer therapy and is a testament to the commitment of our team in making significant strides in the fight against cancer.